Skip to content

Psilocybin research published in 2015

Page 2 of 2: studies 21 to 31 of 31, newest first. Back to the psilocybin overview

Studies

Salvador Roquet, María Sabina, and the Trouble withJipis

Hispanic American Historical Review February 1, 2015 Alexander S. Dawson 16 citations

Abstract While María Sabina has long been an iconic figure among drug enthusiasts and advocates for indigenous rights, her sometime collaborator Salvador Roquet remains largely unknown. This essay introduces the work of this iconoclastic psychiatrist and, in particular, his work with Sabina, highlighting their contributions to the world of psychedelic psychiatry and exploring the nature of...

Drug models of schizophrenia.

Therapeutic Advances in Psychopharmacology February 1, 2015 Hannah Steeds, Robin Carhart-Harris, James Stone 132 citations

Schizophrenia is a complex mental health disorder with positive, negative and cognitive symptom domains. Approximately one third of patients are resistant to currently available medication. New therapeutic targets and a better understanding of the basic biological processes that drive pathogenesis are needed in order to develop therapies that will improve quality of life for these patients....

Legal highs: staying on top of the flood of novel psychoactive substances

Therapeutic Advances in Psychopharmacology January 26, 2015 David Baumeister, Luis M. Tojo, Derek K. Tracy 158 citations

There has been growing clinical, public, and media awareness and concern about the availability and potential harmfulness of so-called ‘legal highs’, which are more appropriately called new or novel psychoactive substances (NPS). A cat-and-mouse process has emerged wherein unknown chemists and laboratories are producing new, and as yet nonproscribed, compounds for human consumption; and as soon...

Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study

Journal of Psychopharmacology January 13, 2015 Michael P. Bogenschutz, Alyssa A. Forcehimes, Jessica Pommy et al. 1,164 citations

Several lines of evidence suggest that classic (5HT2A agonist) hallucinogens have clinically relevant effects in alcohol and drug addiction. Although recent studies have investigated the effects of psilocybin in various populations, there have been no studies on the efficacy of psilocybin for alcohol dependence. We conducted a single-group proof-of-concept study to quantify acute effects of...

DOI: 10.1177/0269881114565144 (opens in new tab) Psilocybin Alcohol Hallucinogen Proof of concept

A Qualitative Report on the Subjective Experience of Intravenous Psilocybin Administered in an fMRI Environment

Current Drug Abuse Reviews January 9, 2015 Samuel Turton, D.j. Nutt, Robin Carhart-Harris 48 citations

This article documents the phenomenology of psilocybin when given in a novel manner (intravenous injection) and setting (an MRI scanner). The findings of the analysis are consistent with previous published work regarding the subjective effects of psilocybin. There is much scope for further research investigating the phenomena identified in this paper.

DOI: 10.2174/1874473708666150107120930 (opens in new tab) Psilocybin Phenomenology philosophy Hallucinogen Interpretative phenomenological analysis +4

Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction

Current Drug Abuse Reviews January 9, 2015 Albert Garcia‐romeu, Roland R. Griffiths, Matthew W. Johnson 480 citations

Psilocybin-occasioned mystical experiences have been linked to persisting effects in healthy volunteers including positive changes in behavior, attitudes, and values, and increases in the personality domain of openness. In an open-label pilot-study of psilocybin-facilitated smoking addiction treatment, 15 smokers received 2 or 3 doses of psilocybin in the context of cognitive behavioral therapy...

New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca

Current Topics in Behavioral Neurosciences 2015 Dennis J. Mckenna, Jordi Riba 31 citations

New World indigenous peoples are noted for their sophisticated use of psychedelic plants in shamanic and ethnomedical practices. The use of psychedelic plant preparations among New World tribes is far more prevalent than in the Old World. Yet, although these preparations are botanically diverse, almost all are chemically similar in that their active principles are tryptamine derivatives, either...

‘Riding the Lines’: The Poetics of the ‘Chevauchements’ in Henri Michaux’s Drug Experiments

Palgrave Macmillan UK eBooks 2015 Mathieu Perrot 1 citation

In 1954, at the age of 55, Henri Michaux was a well-published writer and a seasoned traveller. As a young man in the 1930s and 1940s, the Belgian poet and painter had voyaged across East Asia, Central and South America, which resulted in a large portion of his oeuvre: well-known accounts, both real and imaginary, of his trips abroad, fictional ethnographies, and numerous volumes of poetry....

A persisting perception disorder after cannabis use

Progress in Neurology and Psychiatry 2015 Zoë Ellison‐wright, Ben Sessa 7 citations

Hallucinogen persisting perception disorder is a disorder of uncertain aetiology occurring mainly after ‘classical’ hallucinogen use ( ie mescaline, psilocybin, dimethyltryptamine and LSD) use. Here, the authors describe the case of a boy with similar symptoms developing after he reported using cannabis seven times.

Type and treatment of toxic mushroom poisoning in Korea

Journal of Korean Medical Association 2015 Chang Hwan Sohn 11 citations

To eat unidentified or misidentified mushrooms taken from the wild can be very dangerous. In the vast majority of toxic mushroom ingestions in Korea, the mushroom was incorrectly identified. In general, poisoning of toxic mushrooms can be classified into seven types according to the toxins that they contain; amatoxin, gyromitrin, coprine, muscarine, ibotenic acid-muscimol, psilocybin-psilocin...

Can psychedelic compounds play a part in drug dependence therapy?

The British Journal of Psychiatry 2015 Ben Sessa, Matthew W. Johnson 58 citations

Summary After a 40-year hiatus there is now a revisiting of psychedelic drug therapy throughout psychiatry, with studies examining the drugs psilocybin, ketamine, ibogaine and ayahuasca in the treatment of drug dependence. Limitations to these therapies are both clinical and legal, but the possibility of improving outcomes for patients with substance dependency imposes an obligation to research...